Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C19H23NO3 |
| Molecular Weight | 313.3908 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC1=CC=CC=C1O[C@@H]([C@H]2CNCCO2)C3=CC=CC=C3
InChI
InChIKey=CBQGYUDMJHNJBX-RTBURBONSA-N
InChI=1S/C19H23NO3/c1-2-21-16-10-6-7-11-17(16)23-19(15-8-4-3-5-9-15)18-14-20-12-13-22-18/h3-11,18-20H,2,12-14H2,1H3/t18-,19-/m1/s1
| Molecular Formula | C19H23NO3 |
| Molecular Weight | 313.3908 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including:
https://www.drugs.com/uk/reboxetine-4mg-tablets-leaflet.html | https://www.ncbi.nlm.nih.gov/pubmed/11249515 | https://www.ncbi.nlm.nih.gov/pubmed/14647527
Curator's Comment: description was created based on several sources, including:
https://www.drugs.com/uk/reboxetine-4mg-tablets-leaflet.html | https://www.ncbi.nlm.nih.gov/pubmed/11249515 | https://www.ncbi.nlm.nih.gov/pubmed/14647527
Reboxetine is a selective noradrenergic reuptake inhibitor that acts by binding to the norepinephrine (NE) transporter and blocking reuptake of extracellular NE back into terminals. This compound has low affinity for other transporters and receptors. Reboxetine is used in acute treatment of depressive illness / major depression. Very common side effects are: difficulties to sleep (insomnia); dizziness; dry mouth; constipation; nausea (feeling sick); sweating. Based on studies conducted primarily outside the US, the FDA granted a preliminary letter of approval in 1999. However, more recent clinical studies conducted in the US and Canada, prompted by the FDA, resulted in a letter of non-approval.
CNS Activity
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: Noradrenalin reuptake |
8.0 nM [IC50] | ||
Target ID: Serotonin reuptake |
1.0 µM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | EDRONAX Approved UseReboxetine is indicated for the acute treatment of depressive illness/major depression and for maintaining the clinical improvement in patients initially responding to treatment. |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Discovery of novel selective norepinephrine inhibitors: 1-(2-morpholin-2-ylethyl)-3-aryl-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxides (WYE-114152). | 2011-10-13 |
|
| Antidepressant drugs transactivate TrkB neurotrophin receptors in the adult rodent brain independently of BDNF and monoamine transporter blockade. | 2011 |
|
| [Postoperative pain after transvaginal repair of pelvic organ prolapse with or without mesh]. | 2010-11 |
|
| Pelvic magnetic resonance imaging for assessment of the efficacy of the Prolift system for pelvic organ prolapse. | 2010-11 |
|
| Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. | 2010-10-12 |
|
| [Patent for medical device: from design to marketing (example of Prolift®)]. | 2010-10 |
|
| Transurethral and suprapubic mesh resection after Prolift bladder perforation: a case report. | 2010-10 |
|
| Now or later...Does timing of a midurethral sling in relation to transvaginal prolapse repair affect continence outcomes at 1 year? | 2010-09 |
|
| Vaginal hysterectomy at the time of transvaginal mesh placement. | 2010-09 |
|
| [Transvaginal repair of genital prolapse using the Prolift technique: a prospective study]. | 2010-09 |
|
| Permeation of chlorothalonil through nitrile gloves: collection solvent effects in the closed-loop permeation method. | 2010-07-15 |
|
| Midterm prospective evaluation of TVT-Secur reveals high failure rate. | 2010-07 |
|
| Mid-term results of pelvic organ prolapse repair using a transvaginal mesh: the experience in Sherbooke, Quebec. | 2010-06 |
|
| Optimal primary minimally invasive treatment for patients with stress urinary incontinence and symptomatic pelvic organ prolapse: tension free slings with colporrhaphy, or Prolift with the tension free midurethral sling? | 2010-05 |
|
| [Changes in the length of implanted mesh after reconstructive surgery of the anterior vaginal wall]. | 2010-04 |
|
| [Prolene mesh comparing with sacrospinal fixation in the treatment of genital prolapse in women. Prospective multicentre randomized study]. | 2010-04 |
|
| [Correlation between stress urinary incontinence or urgency and anterior compartment defect before and after surgical treatment]. | 2010-04 |
|
| Transvaginal mesh repair of anterior and posterior vaginal wall prolapse: a clinical and ultrasonographic study. | 2010-04 |
|
| Successful management of depression with reboxetine in a patient who developed Parkinsonism related to paroxetine use. | 2010-04 |
|
| Anatomical and functional outcomes of posterior intravaginal slingplasty for the treatment of vaginal vault or uterine prolapse: a prospective, multicenter study. | 2010-03 |
|
| Does trocar-guided tension-free vaginal mesh (Prolift) repair provoke prolapse of the unaffected compartments? | 2010-03 |
|
| Permeation of herbicidal dichlobenil from a Casoron formulation through nitrile gloves. | 2010-02 |
|
| One-year outcome of concurrent anterior and posterior transvaginal mesh surgery for treatment of advanced urogenital prolapse: case series. | 2009-11-16 |
|
| Laparoscopic sacrohysteropexy and myomectomy for uterine prolapse: a case report and review of the literature. | 2009-11-03 |
|
| [Clinical observation on quality of life of two different operative methods of total pelvic floor reconstruction.]. | 2009-11 |
|
| A serious complication following placement of posterior Prolift. | 2009-11 |
|
| Anatomic outcomes of vaginal mesh procedure (Prolift) compared with uterosacral ligament suspension and abdominal sacrocolpopexy for pelvic organ prolapse: a Fellows' Pelvic Research Network study. | 2009-11 |
|
| Synthetic graft use in vaginal prolapse surgery: objective and subjective outcomes. | 2009-11 |
|
| Short term impact on female sexual function of pelvic floor reconstruction with the Prolift procedure. | 2009-11 |
|
| Trocar-guided total tension-free vaginal mesh repair of post-hysterectomy vaginal vault prolapse. | 2009-10 |
|
| Laparoscopic apical mesh excision for deep dyspareunia caused by mesh banding in the vaginal apex. | 2009-09 |
|
| De novo stress incontinence and pelvic muscle symptoms after transvaginal mesh repair. | 2009-07 |
|
| Changes in levator ani muscle after vaginal hysterectomy and prolapse repair using the Total Prolift procedure. | 2009-07 |
|
| [Transvaginal repair of genital prolapse with prolift: a standardized surgery?]. | 2009-04 |
|
| Perineal approach to vascular anatomy during transobturator cystocele repair. | 2009-04 |
|
| [Choice of a surgical treatment of genital prolapse in women]. | 2009-03-03 |
|
| [Transvaginal repair of genital prolapse with Prolift: evaluation of safety and learning curve]. | 2009-02 |
|
| Implants in operative therapy in women with pelvic organ prolapse--two years of experience. | 2009 |
|
| Vaginal vault prolapse. | 2009 |
|
| Vaginal repair of cystocele with anterior wall mesh via transobturator route: efficacy and complications with up to 3-year followup. | 2009 |
|
| [Surgical treatment of female pelvic organ prolapse at the Clinic of Obstetrics and Gynecology, Hospital of Kaunas University of Medicine]. | 2009 |
|
| Psychopharmacology of ADHD in pediatrics: current advances and issues. | 2009 |
|
| The combined dexamethasone/CRH Test (DEX/CRH test) and prediction of acute treatment response in major depression. | 2009 |
|
| Outcome of treatment of anterior vaginal wall prolapse and stress urinary incontinence with transobturator tension-free vaginal mesh (prolift) and concomitant tension-free vaginal tape-obturator. | 2009 |
|
| Total Prolift System surgery for treatment posthysterectomy vaginal vault prolapse--do we treat both anatomy and function? | 2008-12 |
|
| [Clinical study on concomitant surgery for stress urinary incontinence and pelvic organ prolapse]. | 2008-10-15 |
|
| [Occult stress incontinence identified by preoperative urodynamic study in women with severe pelvic organ prolapse]. | 2008-09 |
|
| Fixed combinations in the management of hypertension: perspectives on lercanidipine-enalapril. | 2008 |
|
| Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive offsodes. | 1997-04 |
|
| Pharmacokinetics of reboxetine in healthy volunteers. Single oral doses, linearity and plasma protein binding. | 1995-08 |
Sample Use Guides
8 mg a day (one 4 mg tablet twice a day). The maximum daily dose should not exceed 12 mg.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:16:47 GMT 2025
by
admin
on
Mon Mar 31 18:16:47 GMT 2025
|
| Record UNII |
947S0YZ36I
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
656118
Created by
admin on Mon Mar 31 18:16:47 GMT 2025 , Edited by admin on Mon Mar 31 18:16:47 GMT 2025
|
||
|
WHO-ATC |
N06AX18
Created by
admin on Mon Mar 31 18:16:47 GMT 2025 , Edited by admin on Mon Mar 31 18:16:47 GMT 2025
|
||
|
WHO-VATC |
QN06AX18
Created by
admin on Mon Mar 31 18:16:47 GMT 2025 , Edited by admin on Mon Mar 31 18:16:47 GMT 2025
|
||
|
NCI_THESAURUS |
C265
Created by
admin on Mon Mar 31 18:16:47 GMT 2025 , Edited by admin on Mon Mar 31 18:16:47 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID1048257
Created by
admin on Mon Mar 31 18:16:47 GMT 2025 , Edited by admin on Mon Mar 31 18:16:47 GMT 2025
|
PRIMARY | |||
|
5858
Created by
admin on Mon Mar 31 18:16:47 GMT 2025 , Edited by admin on Mon Mar 31 18:16:47 GMT 2025
|
PRIMARY | |||
|
127151
Created by
admin on Mon Mar 31 18:16:47 GMT 2025 , Edited by admin on Mon Mar 31 18:16:47 GMT 2025
|
PRIMARY | |||
|
DB00234
Created by
admin on Mon Mar 31 18:16:47 GMT 2025 , Edited by admin on Mon Mar 31 18:16:47 GMT 2025
|
PRIMARY | |||
|
REBOXETINE
Created by
admin on Mon Mar 31 18:16:47 GMT 2025 , Edited by admin on Mon Mar 31 18:16:47 GMT 2025
|
PRIMARY | |||
|
m9514
Created by
admin on Mon Mar 31 18:16:47 GMT 2025 , Edited by admin on Mon Mar 31 18:16:47 GMT 2025
|
PRIMARY | Merck Index | ||
|
CHEMBL14370
Created by
admin on Mon Mar 31 18:16:47 GMT 2025 , Edited by admin on Mon Mar 31 18:16:47 GMT 2025
|
PRIMARY | |||
|
100000078631
Created by
admin on Mon Mar 31 18:16:47 GMT 2025 , Edited by admin on Mon Mar 31 18:16:47 GMT 2025
|
PRIMARY | |||
|
60842
Created by
admin on Mon Mar 31 18:16:47 GMT 2025 , Edited by admin on Mon Mar 31 18:16:47 GMT 2025
|
PRIMARY | RxNorm | ||
|
SUB15112MIG
Created by
admin on Mon Mar 31 18:16:47 GMT 2025 , Edited by admin on Mon Mar 31 18:16:47 GMT 2025
|
PRIMARY | |||
|
C074679
Created by
admin on Mon Mar 31 18:16:47 GMT 2025 , Edited by admin on Mon Mar 31 18:16:47 GMT 2025
|
PRIMARY | |||
|
C72838
Created by
admin on Mon Mar 31 18:16:47 GMT 2025 , Edited by admin on Mon Mar 31 18:16:47 GMT 2025
|
PRIMARY | |||
|
98769-81-4
Created by
admin on Mon Mar 31 18:16:47 GMT 2025 , Edited by admin on Mon Mar 31 18:16:47 GMT 2025
|
SUPERSEDED | |||
|
4808
Created by
admin on Mon Mar 31 18:16:47 GMT 2025 , Edited by admin on Mon Mar 31 18:16:47 GMT 2025
|
PRIMARY | |||
|
71620-89-8
Created by
admin on Mon Mar 31 18:16:47 GMT 2025 , Edited by admin on Mon Mar 31 18:16:47 GMT 2025
|
PRIMARY | |||
|
947S0YZ36I
Created by
admin on Mon Mar 31 18:16:47 GMT 2025 , Edited by admin on Mon Mar 31 18:16:47 GMT 2025
|
PRIMARY | |||
|
2361
Created by
admin on Mon Mar 31 18:16:47 GMT 2025 , Edited by admin on Mon Mar 31 18:16:47 GMT 2025
|
PRIMARY | |||
|
Reboxetine
Created by
admin on Mon Mar 31 18:16:47 GMT 2025 , Edited by admin on Mon Mar 31 18:16:47 GMT 2025
|
PRIMARY | |||
|
7701
Created by
admin on Mon Mar 31 18:16:47 GMT 2025 , Edited by admin on Mon Mar 31 18:16:47 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLIC ENZYME -> INHIBITOR |
IC50
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
MAJOR
|
||
|
METABOLIC ENZYME -> INHIBITOR |
IC50
|
||
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLITE -> PARENT |
IN VITRO
|
||
|
METABOLITE -> PARENT |
IN VITRO
|
||
|
METABOLITE -> PARENT |
IN VITRO
|
||
|
METABOLITE -> PARENT |
IN VITRO
|
||
|
METABOLITE -> PARENT |
IN VITRO
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| Tmax | PHARMACOKINETIC |
|
|
|||
| Biological Half-life | PHARMACOKINETIC |
|
|
|||